Janus Family Kinases (JAK) And Identification Of Immune Modulators
Description of Invention:
This technology relates to an isolated polynucleotide encoding the JAK-3 protein. JAK-3 is a protein tyrosine kinase having a molecular weight of approximately 116 kDa, lacks SH2 or SH3 domains, and is expressed in NK cells and stimulated or transformed T cells, but not in resting T cells. The JAK-3 protein itself, antibodies to this protein, and methods of identifying therapeutic agents for modulating the immune system which make use of the foregoing are described in this invention.
Potential Area of Application:
gene therapy -- SCID
diagnostic -- SCID
research reagent
autoimmune disorders
organ or bone marrow transplantation
Main Advantage of Invention:
isolated JAK-3 protein
antibody to JAK-3 protein
method of screening for immunomodulating agents
JAK-3 only involved in signaling through receptors that contain gc therefore specific drugs will be very selective in their effects
Inventors:
JJ O'Shea (NCI) WJ Leonard (NHLBI) JA Johnston (NIAMS) SM Russell (NHLBI) D McVicar (NCI) M Kawamura (NCI)
Patent Status:
DHHS Reference No. E-094-1994/0 --
U.S. Patent 7,070,972 issued 04 Jul 2006
U.S. Patent Application No. 11/195,197 filed 01 Aug 2005
No foreign rights
Related Technologies: DHHS Reference No. E-176-1995/0 --
U.S. Patent 6,265,160 issued 24 Jul 2001, entitled "Method of Identifying Inhibitors of the JAK-STAT Signal Transduction Pathway," by WJ Leonard
DHHS Reference No. E-079-1993/0 --
U.S. Patent 5,518,880 issued 21 May 1996, entitled "Methods for Diagnosis of XSCID and Kits Thereof," by WJ Leonard, et al.
Relevant Publication:
F Candotti, SA Oakes, JA Johnston, LD Notarangelo, JJ O'Shea, RM Blaese. In vitro correction of JAK3-deficient severe combined immunodeficiency by retroviral-mediated gene transduction. J Exp Med. 1996 June 1;183(6):2687-2692. [PubMed abs]
SM Russell, JA Johnston, M Noguchi, M Kawamura, CM Bacon, M Friedmann, M Berg, DW McVicar, BA Witthuhn, O Silvennoinen, AS Goldman, FC Schmalstieg, JN Ihle, JJ O'Shea, WJ Leonard. Interaction of IL-2R beta and gamma c chains with JAK1 and JAK3: implications for XSCID and XCID. Science 1994 Nov 11;266(5187):1042-1045. [PubMed abs]
T Musso, JA Johnston, D Linnekin, L Varesio, TK Rowe, JJ O'Shea, DW McVicar. Regulation of JAK3 expression in human monocytes: phosphorylation in response to interleukins 2, 4, and 7. J Exp Med. 1995 Apr 1;181(4):1425-1431. [PubMed abs]
SM Russell, N Tayebi, H Nakajima, MC Riedy, JL Roberts, MJ Aman, TS Migone, M Noguchi, ML Markert, RH Buckley, JJ O'Shea, WJ Leonard. Mutation of JAK3 in a patient with SCID: essential role of JAK3 in lymphoid development. Science 1995 Nov 3;270(5237):797-780. [PubMed abs]
Portfolios: Cancer
Cancer -Diagnostics Cancer -Research Materials
For Additional Information Please Contact: Jennifer Wong
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301)435-4633
Email: wongje@mail.nih.gov
Fax: (301)402-0220
